Targets › BRD4
5 programs from 5 companies in 20 trials: 15 Phase 1, 3 Phase 3, 2 Phase 2; Oncology, Other, Infectious disease; next expected readout Nov 2026.
Chromatin reader protein that recognizes and binds acetylated histones and plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure. (UniProt, O60885)
Open in Phaseline: the race on BRD4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Pelabresib Bromodomain and extra-terminal motif (BET) inhibitor | BRD2, BRD4, BRDT, BRD3 | Phase 3 | Hematologic Malignancy; Myelofibrosis; Primary Myelofibrosis (PMF); Healthy Participants … | Nov 2026 |
| National Cancer Institute (NCI) | ZEN003694 (ZEN-3694) BET bromodomain inhibitor | BRD2, BRD3, BRD4 | Phase 2 | Advanced Malignant Solid Neoplasm; Metastatic Colorectal Adenocarcinoma; Anatomic Stage III Breast Cancer AJCC v8; Advanced NUT Carcinoma … | Dec 2026 |
| Resverlogix | Apabetalone (RVX000222) Bromodomain and extra-terminal motif (BET) inhibitor | BRD2, BRD4, BRDT, BRD3 | Phase 2 | Post-Acute COVID-19 Syndrome | – |
| Chia Tai Tianqing Pharmaceutical Group | TQB3617 Capsules Bromodomain and Extra-Terminal (BET) inhibitor | BRD2, BRD3, BRD4, BRDT | Phase 1 | Myelofibrosis | Dec 2026 |
| Bristol-Myers Squibb | Ezobresib (BMS-986158) Bromodomain and extra-terminal motif (BET) inhibitor | BRD2, BRD4, BRDT, BRD3 | Phase 1 | Multiple Myeloma; Myelofibrosis | Aug 2028 |
Myelofibrosis (3) Advanced Malignant Solid Neoplasm (3) Primary Myelofibrosis (PMF) (2) Anatomic Stage III Breast Cancer AJCC v8 (2) Hematologic Malignancy (1) Healthy Participants (1) Advanced Malignancies (1) Advanced Malignancies and Hepatic Impairment (1) Metastatic Colorectal Adenocarcinoma (1) Advanced NUT Carcinoma (1) Recurrent Endometrial Carcinoma (1) Metastatic Colorectal Carcinoma (1)
small molecule (5)
Novartis (1) Chia Tai Tianqing Pharmaceutical Group (1) National Cancer Institute (NCI) (1) Bristol-Myers Squibb (1) Resverlogix (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.